Suppr超能文献

痛泻要方:一种具有治疗溃疡性结肠炎潜力的经典中药方剂。

Tong Xie Yao Fang: A Classic Chinese Medicine Prescription with Potential for the Treatment of Ulcerative Colitis.

作者信息

Chen Kai, Lou Yu, Zhu Ying

机构信息

Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.

Department of Gastroenterology, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China.

出版信息

Evid Based Complement Alternat Med. 2021 Jun 9;2021:5548764. doi: 10.1155/2021/5548764. eCollection 2021.

Abstract

The prescription of Tong Xie Yao Fang (TXYF) was derived from the Yuan dynasty "Dan Brook Heart Law," which was a representative formula for treating liver-spleen disharmony, diarrhea, and abdominal pain. The prescription is composed of four herbs for soothing the liver and strengthening the spleen. TXYF is reportedly capable of eliminating discomfort in ulcerative colitis (UC). This classic formula has been widely used for regulating gastrointestinal motor dysfunction and repairing colon mucosa. This review aims to provide current information on the pharmacology and clinical research of TXYF in the treatment of UC, and to critically appraise that information, in order to guide the future clinical use and experimental study of TXYF in the treatment of UC. We searched online databases including PubMed, CNKI, and Google Scholar for research published between 2010 and 2020 on TXYF and its efficacy in the treatment of UC. The findings indicated that TXYF has anti-inflammatory and immunomodulatory effects, regulates cell signal transduction, brain-gut axis, and intestinal flora in UC, and may promote targeting of bone mesenchymal stem cells (BMSCs) to the colonic mucosa and accelerate healing of the colonic mucosal barrier. In addition, the results of clinical studies showed that TXYF has good efficacy and few adverse reactions in the treatment of UC. Although it has achieved some success, the research is limited by deficiencies; there is a lack of unified standards for the construction of UC animal models and for administration regimen. In addition, the dosage of TXYF is not consistent and lacks pharmacological verification, and clinical trial data are not detailed or sufficiently rigorous. Therefore, a more rigorous, comprehensive, and in-depth study of TXYF in the treatment of UC is needed.

摘要

痛泻要方源自元代的《丹溪心法》,是治疗肝脾不和、腹泻及腹痛的代表性方剂。该方由四味疏肝健脾之药组成。据报道,痛泻要方能消除溃疡性结肠炎(UC)中的不适症状。这一经典方剂已被广泛用于调节胃肠运动功能障碍及修复结肠黏膜。本综述旨在提供痛泻要方治疗UC的药理学及临床研究的当前信息,并对这些信息进行批判性评估,以指导痛泻要方在治疗UC方面的未来临床应用及实验研究。我们在包括PubMed、中国知网和谷歌学术在内的在线数据库中搜索了2010年至2020年间发表的关于痛泻要方及其治疗UC疗效的研究。研究结果表明,痛泻要方具有抗炎和免疫调节作用,可调节UC中的细胞信号转导、脑-肠轴及肠道菌群,还可能促进骨间充质干细胞(BMSC)靶向结肠黏膜并加速结肠黏膜屏障的愈合。此外,临床研究结果显示,痛泻要方治疗UC疗效良好且不良反应较少。尽管已取得了一些成果,但该研究存在局限性;UC动物模型构建及给药方案缺乏统一标准。此外,痛泻要方的剂量不一致且缺乏药理学验证,临床试验数据不详细或不够严谨。因此,需要对痛泻要方治疗UC进行更严格、全面和深入的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710f/8208878/d28abb7918ba/ECAM2021-5548764.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验